Neonatal Respiratory Distress Syndrome vs. Acute Respiratory Distress Syndrome

Newborns with respiratory distress syndrome (NRDS) and adults with acute respiratory distress syndrome (ARDS) share a common clinical presentation—hypoxemic respiratory failure—but arise from fundamentally distinct pathophysiologies, age-specific risk factors, and therapeutic approaches.

Neonatal respiratory distress syndrome, formerly known as hyaline membrane disease, primarily affects preterm infants born before 34 weeks’ gestation. It results from pulmonary surfactant deficiency due to immature type II alveolar epithelial cells. Surfactant—a lipoprotein complex rich in phospholipids (especially dipalmitoylphosphatidylcholine) and surfactant proteins (SP-B and SP-C)—reduces alveolar surface tension, preventing end-expiratory collapse. Without adequate surfactant, widespread atelectasis, ventilation-perfusion mismatch, and intrapulmonary shunting develop, leading to progressive hypoxemia, tachypnea, nasal flaring, grunting, and subcostal retractions. Chest radiography typically reveals diffuse granular opacities and air bronchograms. Antenatal corticosteroid administration to mothers at risk of preterm delivery significantly reduces NRDS incidence by accelerating fetal lung maturation and surfactant synthesis.

In contrast, acute respiratory distress syndrome is a life-threatening inflammatory lung injury affecting older children and adults. It is defined by the Berlin Criteria: onset within one week of a known clinical insult or new/worsening respiratory symptoms; bilateral opacities on chest imaging not fully explained by effusions, lobar/lung collapse, or nodules; respiratory failure not fully attributable to cardiac failure or fluid overload; and impaired oxygenation quantified as PaO₂/FiO₂ ≤ 300 mmHg with PEEP or CPAP ≥ 5 cm H₂O. Common etiologies include sepsis, pneumonia, aspiration, trauma, and pancreatitis. Pathologically, ARDS features diffuse alveolar damage—characterized by alveolar-capillary barrier disruption, neutrophilic infiltration, protein-rich pulmonary edema, and subsequent fibroproliferation. Unlike NRDS, surfactant dysfunction in ARDS is secondary to inflammation-mediated inactivation and altered metabolism—not primary deficiency.

Management strategies reflect these mechanistic differences. NRDS treatment centers on exogenous surfactant replacement (administered via endotracheal tube shortly after birth), gentle ventilation strategies (e.g., nasal CPAP or low-tidal-volume ventilation), and supportive care including thermoregulation and glucose homeostasis. In contrast, ARDS management emphasizes lung-protective ventilation (low tidal volumes of 6 mL/kg predicted body weight, plateau pressure <30 cm H₂O), conservative fluid management when feasible, and treatment of the underlying trigger—such as antibiotics for infection or source control for sepsis. While surfactant therapy has been investigated in ARDS, clinical trials have not demonstrated consistent mortality benefit, underscoring the divergent biological underpinnings of the two syndromes.